PARP1 and cancer: Together, these results suggest that SIK2 inhibitors enhance the vulnerability of cancer cells to olaparib, not only by inhibiting PARP enzyme activity but also by blocking the class-IIa HDAC/MEF2D–mediated DNA repair function.